CapEval Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CapEval Pharma is a specialized consultancy offering strategic and operational support in non-clinical development to pharmaceutical and biotech companies. Founded and led by Dr. Olivier Loget, the firm provides deep expertise in toxicology, safety assessment, and program derisking, helping clients navigate complex development challenges and business transactions. Operating as a pure-service provider with no proprietary assets, it offers flexible engagement models to support a wide range of client needs, from startups to established pharma.

Drug DeliverySmall Molecules

Technology Platform

Integrated consultancy expertise in non-clinical development, toxicology, and regulatory strategy, applied to derisk client drug programs.

Opportunities

Growing demand from virtual and small biotech firms lacking in-house non-clinical expertise creates a expanding client base.

Increasing complexity of novel therapeutic modalities (e.g., gene therapy) requires specialized consulting for non-clinical strategy, presenting new service opportunities.

Risk Factors

High dependence on founder's reputation and network (key person risk).

Revenue is vulnerable to downturns in biopharma R&D spending, as consultancy services are often discretionary.

Competition from larger consulting firms and solo practitioners in a fragmented market.

Competitive Landscape

Operates in a fragmented pharmaceutical consulting market, competing against large multi-service CROs, boutique specialist firms, and independent consultants. Differentiation is based on deep, hands-on non-clinical and toxicology expertise, proven problem-solving ability, and a conflict-free service-only model.

More companies in Digital Health & Biotech SaaS →More companies in France →